Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. reported a reduced net loss of $27.1 million for the six months ended June 30, 2026, an improvement from $36.8 million in the prior year period. Collaboration revenue increased by 43% to $19.3 million. The company also successfully completed a direct offering in January 2026, raising approximately $50.0 million in gross proceeds from the issuance of common stock and warrants. As of June 30, 2026, the company held $68.1 million in cash and cash equivalents and expects its current liquidity to fund operations for at least 12 months.

Foghorn Therapeutics reported a net loss of $7.2 million for the second quarter of 2026, a substantial reduction from $17.9 million in the prior year, driven by increased collaboration revenue of $16.1 million. The company maintains a strong balance sheet with $167.6 million in cash, cash equivalents, and marketable securities, providing a cash runway into the first half of 2028. Operationally, the FHD-909 Phase 1 trial is progressing, and new INDs are targeted for 2027 for selective EP300 degraders and a novel immunology and inflammation program, though the timeline for the selective CBP degrader has been delayed.

Foghorn Therapeutics Inc. announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The event will include a fireside chat on Tuesday, June 9, 2026, at 1:20 p.m. EDT, featuring President and CEO Adrian Gottschalk. Management will also hold one-on-one meetings, and a webcast of the fireside chat will be accessible on the company's investor relations website for 90 days.

Foghorn Therapeutics Inc. reported a net loss of $(19.9) million for Q1 2026, an increase from $(18.8) million in Q1 2025. The company successfully completed a direct offering in January 2026, raising approximately $50.0 million through the issuance of common stock and warrants. This financing significantly improved the company's cash position and reduced its stockholders' deficit, providing funding for at least the next 12 months despite continued operating losses.

Foghorn Therapeutics reported its first quarter 2026 financial results and provided a comprehensive corporate and pipeline update. The company's lead program, FHD-909, is on track in its Phase 1 trial, with promising preclinical data for combination therapy. Additionally, Foghorn is advancing its wholly-owned selective CBP and EP300 degrader programs, with INDs anticipated in 2027, and its ARID1B degrader program towards in vivo proof of concept in 2026. Despite a slight increase in net loss to $19.9 million and a decrease in collaboration revenue to $3.3 million, the company maintains a strong balance sheet with $183.6 million in cash, providing a runway into the first half of 2028.

Foghorn Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 24, 2026. Stockholders will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and advisory proposals regarding executive compensation and its frequency. The record date for voting is April 27, 2026.

Foghorn Therapeutics presented its strategic position as a leader in chromatin biology, emphasizing its Gene Traffic Control Platform® for developing precision therapeutics. The company highlighted its focus on drugging challenging targets implicated in up to 50% of all tumors, aiming for first-in-class and best-in-class approaches. This update underscores Foghorn's potential in unlocking multi-billion dollar opportunities through selective target engagement and its ongoing strategic partnership with Lilly, including a Phase 1 trial for FHD-909.

Foghorn Therapeutics presented new preclinical data at AACR 2026, highlighting significant progress across its pipeline. The SMARCA2 inhibitor FHD-909 showed complete and durable tumor regression with immune memory when combined with an anti-PD-1 antibody. Additionally, selective CBP and EP300 degraders demonstrated favorable efficacy and safety profiles in various cancer models, with the EP300 degrader outperforming a clinical benchmark. The company also reported robust degradation with its ARID1B degraders, indicating potential for oral bioavailability.